Company intelligence / Profile preview

ART Medical

Ownership: Private
Development stage: Commercial

Overview

ART Medical's smART+ Platform has demonstrated, in a randomized comparative study, the ability to reduce ICU patients' length of stay and ventilation by more than three days. The technology establishes a direct correlation between optimized nutrition delivery in the ICU and improved patient outcomes[3].

The platform has received CE Mark and AMAR clearance, with clinical use at leading hospitals such as Rabin Medical Center. Clinical results have been published by ESPEN’s Clinical Nutrition journal[3].

Therapeutic areas: PulmonologyMetabolic DisordersNephrologyInfectious Diseases
Modalities: DeviceSoftware
Industry: Physiological Monitoring

Partnerships

Teva Israel[3]

Beyond the preview

Go deeper on ART Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART Medical.

Explore the full profile